The Institutional Biosafety Committee (IBC) advises on matters relating to the safe handling, transport, use, and disposal of biological materials, including recombinant or synthetic nucleic acid molecules molecules, on the Urbana-Champaign campus. The committee reports to the Vice Chancellor of Research and is co-chaired by Carol Maddox and Mary Kraft. Questions? email firstname.lastname@example.org or call 217.333.2755.
All work with materials requiring registration must be approved by the IBC prior to initiation.
The following materials require registration with the IBC:
*Due to the COVID-19 pandemic, the IBC has instituted Interim Biosafety Guidelines when handling primary human and non-human materials.
The university is responsible for ensuring that all recombinant or synthetic nucleic acid research, irrespective of funding source, is conducted "in full conformity with the provisions of the NIH Guidelines." To ensure compliance with the guidelines, campus policy requires that all recombinant or synthetic nucleic acid work must be registered with the IBC. Work cannot begin on projects involving recombinant or synthetic nucleic acids until the Principal Investigator (PI) receives a notice from the Division of Research Safety and/or the IBC allowing the initiation of work. NIH penalties for university/PI noncompliance may result in: (i) suspension, limitation, or termination of NIH funds for recombinant or synthetic nucleic acid research at the university, or (ii) a requirement for prior NIH approval of any or all recombinant or synthetic nucleic acid projects at the university.
For a preview of the project registration questions click the Registration Forms Preview PDF. The PDF is intended for preview purposes only and will not be accepted as a project registration.
The IBC meets once per month as per the following schedule. Complete registration information must be submitted by 5 p.m. on the submission deadline date before the meeting at which your project will be reviewed.
September 17, 2021
October 12, 2021
October 15, 2021
November 9, 2021
November 19, 2021
December 14, 2021
December 17, 2021
January 11, 2022
January 14, 2022
February 8, 2022
February 11, 2022
March 8, 2022
March 18, 2022
April 12, 2022
Once submitted, you will receive an email confirming receipt of the registration. In most cases,* the project will be assigned to a panel of faculty reviewers who will verify your risk assessment for the proposed work. On-line forms will be in PDF format so that changes cannot be made during the initial review. Review questions will be attached directly to the registration. When the review is complete, the PI and those with editing capabilities will be notified via email that their response is required. Simultaneously, the biosafety professional overseeing the project review will determine if any BL-2 or ABL-2 audits are required. All rooms where work will be performed at Biosafety Level 2 or Animal Biosafety Level 2 must be audited on a regular basis.
Approvals will not be issued until all questions and audit findings have been addressed and all required training completed.
*Some lower risk projects (e.g,. Recombinant DNA projects requiring Biosafety Level 1 containment) may qualify for review by a DRS research safety professional. In these situations, the review process may be expedited. However, the best approach is to plan for the timeline outlined above and in the Submission Deadline/Meeting Schedule section.
NIH requires training when performing experiments with recombinant or synthetic nucleic acids including transgenic plants and animals (including knockouts). This training requirement will be met by completion of the NIH Guidelines Overview module.
Basic training requirements for all laboratories are outlined on the Safety Training Checklist webpage as part of a required Laboratory Safety Plan. This includes the on-line training module, Laboratory Safety.
Additional training and information specific to work at Biosafety level 2 should include:
Review of the following DRS Guidance documents for all equipment being used in the laboratory:
Review of the following DRS Guidance documents for all applicable waste generated in the laboratory:
Some scientific and technological advances that provide great benefits to society can also be used maliciously. Research yielding new technologies or information with the potential for both benevolent and malevolent applications is referred to as "dual use research". This small subset of life sciences research with the highest potential for yielding knowledge, products, or technology that could be directly misapplied to threaten public health or national security is referred to as "Dual Use Research of Concern (DURC)."
The United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern outlines the criteria for what qualifies as DURC. A list of the 15 agents and toxins and descriptions of the 7 experimental effects for potential DURC research are found here.
To better understand the DURC requirements and when research meets the DURC criteria, the NIH-Office of Sciences Policy provides an overview and case study approach for research that requires oversight of life sciences DURC.
A one time online training entitled DURC Policy Overview is required to be taken by the following campus personnel;
To comply with the US government DURC policy, a campus Institutional Review Entity (IRE) has been established to review research for DURC which is coordinated through the IBC.
It is the responsibility of the Principal Investigator to identify research involving one or more of the agents and toxins on the DURC list and notify the IRE-IBC for review of its DURC potential. The formal review starts with the PI submission of the DURC Review Application which is submitted to email@example.com in conjunction with the IBC registration to determine whether or not the project meets the DURC definition. For research that is determined to be DURC, a subcommittee will work with the PI to draft a risk mitigation plan to be submitted to the applicable US government funding agency.